Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFNγ producing ILCs and T cells.

20 , 21 Oral tofacitinib treatment after infection had no effect on S100a8 expression while Muc1 expression was downregulated and S100a9 expression showed a trend to reduction ( Fig. 1H ).

also in 53,322 other papers